NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th February 2009 The US Food and Drug Administration has published information about an ongoing safety review of clopidogrel. This follows reports suggesting it is less effective in some […]
Category Archives: Cardiovascular disease
NPC Archive Item: Fish oils don’t reduce arrhythmias or all cause mortality, but may reduce deaths from cardiac causes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A recent systematic review found no benefit for fish oil supplements in reducing the risk of sudden cardiac death or all cause mortality. There was a reduction in death […]
NPC Archive Item: MeReC Bulletin on lipid modification now published
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. This MeReC Bulletin summarises the NICE guidance on lipid modification and addresses some important supplementary clinical questions. The most recent MeReC Bulletin: Lipid-modifying treatment (Vol. 19, No. 3) is […]
NPC Archive Item: Meta-analysis demonstrates statins benefit on total mortality in primary prevention
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A recent systematic review of statins for primary prevention reports that statins significantly reduced the risk of major cardiovascular events, mortality from cardiovascular disease and total mortality. Action: This […]
NPC Archive Item: Is one beta-blocker better than another in heart failure?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A large cohort study found that among patients admitted with heart failure, the adjusted risk of death in the following 12 months was similar among patients taking atenolol and […]
NPC Archive Item: Rivaroxaban (Xarelto®▼) reduces symptomatic VTE and death more than enoxaparin in patients undergoing hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Results from a pre-specified pooled analysis of the four, double-blind, double-dummy phase 3 (RECORD) studies have been presented as a conference abstract at the 50th Meeting of the American […]
NPC Archive Item: Dual antihypertensive therapy in patients at high risk of CV disease (ACCOMPLISH study)
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The ACCOMPLISH study suggests that in patients at high risk of CV disease, and who require dual antihypertensive therapy to control blood pressure, a combination of an ACE inhibitor […]
NPC Archive Item: Irbesartan ineffective in heart failure with preserved LV ejection fraction
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The I-PRESERVE study found no evidence to support the routine use of an A2RA in patients with heart failure and a preserved left ventricular ejection fraction. Action This data […]
NPC Archive Item: Is lower cholesterol better? – the SEARCH continues
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Early results of the SEARCH study have been presented at the American Heart Association conference and as such have not yet been fully evaluated. They suggest no statistically significant […]
NPC Archive Item: Higher dose rosuvastatin in lower risk patients – the JUPITER study
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. In the JUPITER study, rosuvastatin 20mg daily reduced the risk of major CV events compared with placebo in people with few elevated CV risk factors apart from a raised […]